Eli Lilly (LLY) Accumulated Expenses (2009 - 2026)

Eli Lilly (LLY) has reported Accumulated Expenses for 18 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.4 billion, up 22.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 22.0% YoY), and the FY2025 annual result was $2.4 billion, up 13.42% from the prior year.
• Accumulated Expenses was $1.4 billion for Q1 2026 at Eli Lilly, down from $2.4 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.4 billion in Q4 2025 and troughed at $693.1 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2024.
• The widest YoY moves for Accumulated Expenses: up 55.73% in 2023, down 3.82% in 2023.
• Over 5 years, Accumulated Expenses stood at $1.1 billion in 2022, then surged by 55.73% to $1.7 billion in 2023, then gained by 26.88% to $2.1 billion in 2024, then rose by 13.42% to $2.4 billion in 2025, then slumped by 42.78% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.0 billion in Q3 2025.